Abstract:Background and Purpose Rivaroxaban is emerging as a viable anticoagulant
for the pharmacological management of cancer associated venous
thromboembolism (CA-VTE). Being eliminated via CYP3A4/2J2-mediated
metabolism and organic anion transporter 3
(OAT3)/P-glycoprotein-mediated renal secretion, rivaroxaban is
susceptible to drug-drug interactions (DDIs) with protein kinase
inhibitors (PKIs), erlotinib and nilotinib. Physiologically based
pharmacokinetic (PBPK) modelling was applied to interrogate the DDIs for
do… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.